Literature DB >> 4056900

Chiasmatic optic glioma treated with chemotherapy. A preliminary report.

J G Rosenstock, R J Packer, L Bilaniuk, D A Bruce, J L Radcliffe, P Savino.   

Abstract

Chiasmatic optic glioma is a rare tumor with an erratic natural history, usually seen in young children. A prior study from this institution demonstrated that these lesions were frequently lethal, despite initial clinical stabilization following radiation therapy, and that visual, intellectual, and late endocrinological disabilities were prevalent. A novel approach was developed in 1977, when an initial clinical response to vincristine was recorded in a child with a recurrent optic glioma. Since then, all children with recurrent optic glioma and all children aged 6 years old and under with newly diagnosed optic glioma have been offered a program of initial therapy with vincristine and actinomycin D for six cycles over 18 months. The four children with recurrent tumor who were treated with that regimen remain clinically stable 13 to 115 months after chemotherapy. Twelve children (eight under 24 months old) with newly diagnosed optic glioma have been treated with this program, and three are still on therapy. Four developed progression while on therapy, and five remain stable from 1 to 60 months posttherapy. The four children who developed progressive disease have been treated with radiation therapy and remain stable. Six of the 12 children showed shrinkage of their tumor on computerized tomography while receiving chemotherapy. This program may serve as an alternative to initial radiation therapy in young children.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4056900     DOI: 10.3171/jns.1985.63.6.0862

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  14 in total

1.  Visual pathway glioma: an erratic tumour with therapeutic dilemmas.

Authors:  A Shuper; G Horev; L Kornreich; S Michowiz; R Weitz; R Zaizov; I J Cohen
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

Review 2.  Spontaneous regression of optic pathways gliomas in three patients with neurofibromatosis type I and critical review of the literature.

Authors:  Manolo Piccirilli; Jacopo Lenzi; Catia Delfinis; Guido Trasimeni; Maurizio Salvati; Antonino Raco
Journal:  Childs Nerv Syst       Date:  2006-04-26       Impact factor: 1.475

Review 3.  Treatments for astrocytic tumors in children: current and emerging strategies.

Authors:  Stanislaw R Burzynski
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

4.  Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study.

Authors:  V M Aquino; D W Fort; B A Kamen
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

Review 5.  Neurofibromatosis and optic pathways gliomas.

Authors:  E M Housepian; T L Chi
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

Review 6.  Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low grade glioma.

Authors:  Giorgio Perilongo
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

Review 7.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 8.  An integrated approach to the treatment of chiasmatic-hypothalamic gliomas.

Authors:  M Garvey; R J Packer
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

9.  Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era.

Authors:  C Cappelli; J Grill; M Raquin; A Pierre-Kahn; A Lellouch-Tubiana; M J Terrier-Lacombe; J L Habrand; D Couanet; R Brauner; D Rodriguez; O Hartmann; C Kalifa
Journal:  Arch Dis Child       Date:  1998-10       Impact factor: 3.791

Review 10.  Chemotherapeutic treatment of extensive optic pathway tumors in infants.

Authors:  C S Kretschmar; R M Linggood
Journal:  J Neurooncol       Date:  1991-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.